Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Boussinesq, J. Gardon, N. Gardon-Wendel, J. Chippaux (2003)
Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in CameroonFilaria Journal, 2
S. Meredith, H. Dull (1998)
Onchocerciasis: The First Decade of Mectizan™ TreatmentParasitology Today, 14
T. Geary (2005)
Ivermectin 20 years on: maturation of a wonder drug.Trends in parasitology, 21 11
L. Kelly-Hope, J. Cano, M. Stanton, M. Bockarie, D. Molyneux (2014)
Innovative tools for assessing risks for severe adverse events in areas of overlapping Loa loa and other filarial distributions: the application of micro-stratification mappingParasites & Vectors, 7
N. Twum-Danso, S. Meredith (2003)
Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co‐endemic for loiasisTropical Medicine & International Health, 8
Michael D’Ambrosio, M. Bakalar, S. Bennuru, Clay Reber, A. Skandarajah, Lina Nilsson, N. Switz, J. Kamgno, S. Pion, M. Boussinesq, T. Nutman, D. Fletcher (2015)
Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscopeScience Translational Medicine, 7
A. Hoerauf, K. Pfarr, S. Mand, A. Debrah, S. Specht (2011)
Filariasis in Africa--treatment challenges and prospects.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 17 7
N. Twum-Danso (2003)
Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the futureFilaria Journal, 2
J. Kamgno, M. Boussinesq, F. Labrousse, B. Nkégoum, B. Thylefors, C. Mackenzie (2008)
Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp.The American journal of tropical medicine and hygiene, 78 4
J. Bof, V. Maketa, D. Bakajika, F. Ntumba, D. Mpunga, M. Murdoch, A. Hopkins, M. Noma, H. Zouré, A. Tekle, M. Katabarwa, P. Lutumba (2015)
Onchocerciasis control in the Democratic Republic of Congo (DRC): challenges in a post‐war environmentTropical Medicine & International Health, 20
C. Mackenzie, T. Geary, R. Prichard, M. Boussinesq (2007)
Where next with Loa loa encephalopathy? Data are badly needed.Trends in parasitology, 23 6
J. Gardon, N. Gardon-Wendel, Demanga-Ngangue, J. Kamgno, J. Chippaux, M. Boussinesq (1997)
Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infectionThe Lancet, 350
D. Molyneux, M. Bradley, A. Hoerauf, D. Kyelem, M. Taylor (2003)
Mass drug treatment for lymphatic filariasis and onchocerciasis.Trends in parasitology, 19 11
N. Twum-Danso (2003)
Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported casesFilaria Journal, 2
(2013)
African Programme for Onchocerciasis Control: meeting of National Onchocerciasis Task Forces, September 2013.Releve epidemiologique hebdomadaire, 88 50
B. Duke (2003)
Overview: Report of a Scientific Working Group on Serious Adverse Events following Mectizan® treatment of onchocerciasis in Loa loa endemic areas.Filaria Journal, 2
L. Kelly-Hope, B. Thomas, M. Bockarie, D. Molyneux (2011)
Lymphatic filariasis in the Democratic Republic of Congo; micro-stratification overlap mapping (MOM) as a prerequisite for control and surveillanceParasites & Vectors, 4
J Kamgno, M Boussinesq, F Labrousse, B Nkegoum, BI Thylefors, CD Mackenzie (2008)
Case Report: encephalopathy after Ivermectin treatment in a patient infected with Loa loa and Plasmodium spp.Am J Trop Med Hyg, 78
M. Boussinesq, J. Gardon, N. Gardon-Wendel, J. Kamgno, Pierre Ngoumou, Jean-Philippe Chippaux (1998)
Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis.The American journal of tropical medicine and hygiene, 58 4
Drugs - Real World Outcomes (2017) 4:151–158 DOI 10.1007/s40801-017-0110-0 OR IGINAL RESEARCH ARTIC L E Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System 1,2,3 1 2,3 4 • • • • Didier Nzolo Francis Anto Sarah Hailemariam Didier Bakajika 5 6 2,3 2,3,7 • • • • Daniel Muteba Jean-Claude Makenga Gautier Mesia Celestin Nsibu 2,3,8 2,3 Samuel Mampunza Gaston Tona Published online: 9 June 2017 The Author(s) 2017. This article is an open access publication Abstract mectin in the DRC were extracted from the World Health Introduction The mainstay of onchocerciasis control cur- Organization (WHO) Global individual case safety report rently is mass administration of ivermectin; however, this (ICSR) database (VigiBase). The review covered the per- may be associated with serious adverse events, including iod 2009–2013 and focused on central and peripheral deaths, when administered in areas where onchocerciasis nervous system disorders. Relevant demographic, clinical, and loiasis are co-endemic. and parasitological data, including age, sex, area of resi- Objectives The objective of the current study was to dence, adverse events, and parasite density were extracted. describe the central and peripheral nervous system disor- Descriptive
Drugs - Real World Outcomes – Springer Journals
Published: Jun 9, 2017
Access the full text.
Sign up today, get DeepDyve free for 14 days.